{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:20:56Z","timestamp":1772778056521,"version":"3.50.1"},"reference-count":2,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1038\/s41581-023-00795-w","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T10:02:28Z","timestamp":1701079348000},"page":"6-6","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Renoprotective effects of sparsentan: clinical trial evidence in IgA nephropathy and FSGS"],"prefix":"10.1038","volume":"20","author":[{"given":"Monica","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"795_CR1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308550","author":"MN Rheault","year":"2023","unstructured":"Rheault, M. N. et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N. Eng. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2308550 (2023)","journal-title":"N. Eng. J. Med."},{"key":"795_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02302-4","author":"BH Rovin","year":"2023","unstructured":"Rovin, B. H. et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(23)02302-4 (2023)","journal-title":"Lancet"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00795-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00795-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00795-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T14:07:45Z","timestamp":1702649265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00795-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":2,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["795"],"URL":"https:\/\/doi.org\/10.1038\/s41581-023-00795-w","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"27 November 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}